News articles about Medifast (NYSE:MED) have been trending somewhat positive on Friday, Alpha One Sentiment reports. The research group, a service of Accern, rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Medifast earned a news impact score of 0.11 on Alpha One’s scale. Alpha One also gave headlines about the specialty retailer an impact score of 68 out of 100, indicating that recent press coverage is likely to have an effect on the stock’s share price in the near future.
A number of research analysts recently weighed in on MED shares. Zacks Investment Research raised Medifast from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Friday, March 24th. Sidoti downgraded Medifast from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 2nd.
Shares of Medifast (NYSE:MED) traded down 0.93% during mid-day trading on Friday, hitting $42.80. The stock had a trading volume of 102,367 shares. Medifast has a 52-week low of $30.00 and a 52-week high of $47.35. The stock’s 50-day moving average price is $44.88 and its 200-day moving average price is $42.66. The firm has a market cap of $510.48 million, a PE ratio of 26.10 and a beta of 0.54.
Medifast (NYSE:MED) last posted its quarterly earnings data on Thursday, May 4th. The specialty retailer reported $0.51 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.02. The business had revenue of $70.62 million for the quarter, compared to analysts’ expectations of $72.36 million. Medifast had a return on equity of 24.64% and a net margin of 6.43%. The business’s revenue was down 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.42 EPS. On average, analysts anticipate that Medifast will post $2.03 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, May 9th. Shareholders of record on Thursday, March 23rd were given a dividend of $0.32 per share. The ex-dividend date was Tuesday, March 21st. This represents a $1.28 annualized dividend and a yield of 2.96%. Medifast’s payout ratio is 85.91%.
In related news, Director Glenn W. Welling purchased 17,084 shares of the company’s stock in a transaction dated Tuesday, March 14th. The shares were purchased at an average cost of $41.33 per share, with a total value of $706,081.72. Following the transaction, the director now directly owns 5,309 shares in the company, valued at approximately $219,420.97. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 6.47% of the company’s stock.
Medifast Company Profile
Medifast, Inc is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins.
Receive News & Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related companies with MarketBeat.com's FREE daily email newsletter.